Overview

Bioequivalence Bewteen DopaSnap® (Cabidopa/Levopdoap 25/100 mg Tablet) and Carbidopa/Levodopa 25/100 mg Tablet (Actavis)

Status:
Completed
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
This will be a single center, bioequivalence and food-effect, open-label study designed to be conducted in three sequential parts:
Phase:
Phase 1
Details
Lead Sponsor:
Riverside Pharmacueticals Corporation
Treatments:
Carbidopa
Carbidopa, levodopa drug combination
Levodopa